Tag Archives: sodium-glucose co-transporter 2 (SGLT2) inhibitor
February 2023 Br J Cardiol 2023;30:7–9 doi:10.5837/bjc.2023.003
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two new meta-analyses
Kaitlin J Mayne, David Preiss, William G Herrington
Vaduganathan et al. aggregated results from five heart failure trials,3 and the Nuffield Department of Population Health Renal Studies Group with the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium combined standardised data from 13 large placebo-controlled SGLT2 inhibitor trials from three different patient populations. It included results from trials studying 42,568 patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, 21,974 patients in heart failure trials, and 25,898 patients in CKD trials.4 Across the 13 trials, the risk of the composite of hospitalisation for heart failure or cardiovas
January 2022 Br J Cardiol 2022;29:12–15 doi:10.5837/bjc.2022.002
Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy
Kieran F Docherty, John J V McMurray
Introduction To date, five pharmacological approaches have been demonstrated to significantly reduce the risk of mortality and prevent hospitalisation for worsening heart failure (HF) in patients with HF with reduced ejection fraction (HFrEF): the combination of a neprilysin inhibitor and an angiotensin-receptor blocker (i.e. sacubitril/valsartan), a beta blocker, a mineralocorticoid-receptor antagonist (MRA) and a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Hereafter, these five agents, which can be prescribed as four pills, will be referred to as the ‘four foundational therapies for HFrEF’.1-11 The combination of these four ther
For healthcare professionals only
